Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course
|
|
|
- Susan Gallagher
- 10 years ago
- Views:
Transcription
1 The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) through the Approved Continuing Education ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2013 6/12/2016. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive (clinical or social work ethics) continuing education clock hours. PC1 - Pre-Conference Session Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course Discuss basic information regarding medication assisted treatment developed by the National Alliance for Medication Assisted Treatment (NAMA Recovery). Develop an understanding about the science of addiction Describe the laws behind methadone and buprenorphine treatment Identify basic tools to work as an advocate. Explain how advocacy and the media respond to each other and how to properly handle different situations. Identify ways to use advocacy to change policy. Analyze advocacy campaigns to target an issue or respond to negative and incorrect information about medication assisted treatment. Describe the basic ethics for being an advocate and types of advocacy including handling grievances, systems advocacy, education of policy makers and the community. Credit Hours: 8 PC2 - Pre-Conference Session Title: Buprenorphine and Office-Based Treatment of Opioid Dependence Identify goals of the course and discuss their relevance to opioid dependence. Discuss buprenorphine efficacy and safety. Identify legislative changes.
2 Describe patient selection. Demonstrate clinical use of buprenorphine. Discuss non-pharmacological interventions Discuss medical and psychiatric conditions in opioid dependent patients. Discuss special treatment populations. Demonstrate office procedures. Credit Hours: 8.5 PC3 - Pre-Conference Session Title: Opioid Dependence in Peri-Partum Women: Policy, Collaboration, and Strategy Identify collaborative partnerships necessary in developing a coordinated response between child welfare, substance abuse treatment, medication assisted treatment, family court and medical professionals. To identify promising practices being implemented to improve outcomes for women with opioid dependency and their infants exposed in utero. Describe effective strategies and technical assistance needed by pregnant and postpartum women treatment programs. PC4 - Pre-Conference Session Title: OTP Clinical Staff Education Workshop Define best clinical practice to reduce morbidity and mortality associated with methadone maintenance therapy (MMT) in opioid addiction patients. Identify the risks associated with use of methadone in MMT Describe the unique characteristics of methadone pharmacology and pharmacotherapy. Demonstrate opioid treatment program (OTP) patient screening, assessment, induction, stabilization and maintenance techniques in MMT.
3 Identify and address co-occurring medical/psychiatric disorders that are seen in opioid addicted patients. Design treatment services and levels of care for patients in MMT. Course Target Audience: Beginning & Intermediate Credit Hours: 7 PC5 - Pre-Conference Session Title: Nurses and Opioid Treatment Programs Define Best Practice Guidelines for nurses working in an opioid treatment program setting. Identify key practice recommendations pertaining to nurses role in Medication Assisted Treatment. Identify educational, organizational, and policy recommendations to create a supportive environment for nurses. Course Target Audience: Beginning & Intermediate PC6 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.
4 PC7 - Pre-Conference Session Title: New and emerging medications for the treatment of opioid use disorder Describe medications for treating opioid dependence and overdose. Compare and contrast the use of MAT and naltrexone for opioid dependence. Discuss the use of non-opioid medications for the treatment of opioid use disorder and its impact on treatment adherence. PC8 - Pre-Conference Session Title: Opioid Maintenance Pharmacotherapy: A Course for Clinicians Identify interest in the field of Medication Assisted Treatment (MAT) of opioid dependence. Identify best practices in MAT Describe and discuss current challenges and relevant case studies to facilitate understanding of didactic principles. Describe how to deliver safe and effective MAT for patients with opioid dependence. Credit Hours: 8.5 PC9 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.
5 PC10 - Pre-Conference Session Title: Intersection of Pain and Addiction: Research and Clinical Practice Describe the neuropsychobiology of pain and explain the need for multidimensional treatment in patients with co-morbid pain and opioid addiction. Identify specific issues related to acute and chronic pain in patients in opioid treatment programs. Identify effective assessment and treatment strategies for patients with co-morbid pain and opioid dependence. PC11 - Pre-Conference Session Title: State Opioid Treatment Authority Meeting Identify federal and state regulatory entities overseeing the use of medication assisted treatment (MAT). Identify best practices in providing oversight of MAT. Describe strategies to improve joint regulatory monitoring of OTPs. Identify strategies to promote joint oversight and compliance with established protocols in medication assisted treatment. Credit Hours: 8
6 PC12 - Pre-Conference Session Title: Opioid Treatment Program Accreditation Town Hall Meeting Identify and discuss new standards, initiatives & tools available through The Joint Commission. Describe how to implement updated or revised Joint Commission accreditation standards and explain how to access new tools & resources available through The Joint Commission. Develop a patient plan for care, treatment & services that is compliant with all related Joint Commission standards. PC13 - Pre-Conference Session Title: Recovery and Medication Assistance Treatment Identify principles that can be applied for individuals using medication in their recovery. Identify key factors in implementing a peer mentoring program. Describe important resources for organizations to access to improve patient care and assist in the recovery process.
7 PC14 - Pre-Conference Session Title: Managing Workplace Risks: Ten Things Employers Need to Known in 2015 to Avoid Workplace Legal Claim Identify employment litigation as it relates to OTPs. Describe how regulatory changes and state and federal case holdings affect the workforce. Describe risk reduction strategies for employers. Identify strategies to promote compliance with established protocols in medication assisted treatment. Course Target Audience: Advanced PC15 - Pre-Conference Session Title: OTP Liability for Patient-Related Motor Vehicle Accidents: A Mock Trial and Focus Group Presentation Identify the risk of opioid treatment programs (OTPs) liability for patients in medication assisted treatment. Develop knowledge about approved policies to treat chronic opioid addiction. Describe current regulations explained by judicial personnel working within the systems. PC16 - Pre-Conference Session Title: Presentation by the World Federation for the Treatment of Opioid Dependence Identify strategies implemented by patients who misuse opiates/opioids while in opioid maintenance treatment. Discuss measurable outcomes in opioid dependence care. Analyze the effects of agonist opioid treatment on sexual dysfunctions.
8 Identify strengths and limitations of replacement therapy method resettlement in prisons. Describe emerging trends in alternative routes for prescription drug misuse in Europe. Describe the utilization of motivational interviewing to facilitate 12 steps for opiate addiction. Explain existing and future treatments and prevention of hepatitis C. Identify factors associated with outcome of inpatient opioid addiction treatment. Identify risk factors for weight gain among patients in methadone maintenance treatment. Discuss the utilization of naloxone in an effort to prevent opioid overdose. Describe effectiveness of medications utilized in the treatment of opioid addiction. Describe the work of the World Federation for the Treatment of Opioid Dependence PC17 - Pre-Conference Session Title: Overdose Prevention Implementation Strategies Describe the significant need for both systemic and individual interventions for healthcare professionals and first responders to address opioid overdoses. Identify current evidence for the administration of naloxone to reverse opioid overdoses by bystanders. Describe steps in the utilization of naloxone to reverse opioid overdose.
Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis
The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,
Web-Based Resources. Locating Treatment
Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate
Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
Governor s Task Force on Mental Health and Substance Use. www.ncdhhs.gov/mhsu
Governor s Task Force on Mental Health and Substance Use www.ncdhhs.gov/mhsu Problem Statement 97 Painkiller prescriptions per 100 North Carolinians Number of deaths by drug overdose in North Carolina
John R. Kasich, Governor Orman Hall, Director
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
TREATMENT MODALITIES. May, 2013
TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section TITLE I: PREVENTION SUBTITLE A- PRESCRIBER EDUCATION PRACTITIONER EDUCATION This subtitle requires practitioners who
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015
Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid
IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act
IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This
Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.
Addiction Psychiatry Program Site Specific Goals and Objectives Addiction Psychiatry (ADTU) Goal: By the end of the rotation fellow will acquire the knowledge, skills and attitudes required to recognize
Treatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health
TESTIMONY of the American Medical Association before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Re: Examining Legislative Proposals to Combat our Nation's
EPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
Prescriber Behavior, Pain Treatment and Addiction Treatment
Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy
Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Alcohol and Drug Abuse Treatment Centers
Division of State Operated Healthcare Facilities Alcohol and Drug Abuse Treatment Centers Jenny Wood Interim ADATC Team Leader HHS LOC Mental Health Subcommittee February 24, 2014 ADATC Locations R.J.
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper
Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper July 2, 2015 B. Steven Bentsen MD, DFAPA Board certified in Addiction Medicine Opioid Addiction Is Headline News Why? There
STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council
STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council PRIORITY AREA: PRESCRIBERS Recommendation: The Council recommends that
Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015
s for the Prevention and Treatment of Substance Use Disorders Prepared by Mental Health Legal Advisors Committee November 2015 Acro ABH ACA A- CRA ACC Association A statewide association ABH of Behavioral
Care Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
Addiction Psychiatry Fellowship Rotation Goals & Objectives
Addiction Psychiatry Fellowship Rotation Goals & Objectives Table of Contents University Neuropsychiatric Institute (UNI) Training Site 2 Inpatient addiction psychiatry rotation.....2 Outpatient addiction
How To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
Performance Standards
Performance Standards Co-Occurring Disorder Competency Performance Standards are intended to provide a foundation and serve as a tool to promote continuous quality improvement and progression toward best
Buprenorphine Therapy in Addiction Treatment
Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry
HOPE Helping Opiate- Addicted Pregnant women Evolve
HOPE Helping Opiate- Addicted Pregnant women Evolve Medical Director: Michael P. Marcotte, MD TriHealth-Good Samaritan Hospital Cincinnati Ohio MHAS MOMs Grant 2014-2016 Ohio MHAS MOMs Grant 2014-2016
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,
Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia
Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE
FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015
LEGISLATIVE SERVICES AGENCY OFFICE OF FISCAL AND MANAGEMENT ANALYSIS 200 W. Washington, Suite 301 Indianapolis, IN 46204 (317) 233-0696 http://www.in.gov/legislative FISCAL IMPACT STATEMENT LS 7351 NOTE
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Opioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Licensure of Substance Abuse Treatment Programs Required Amendments
Licensure of Substance Abuse Treatment Programs Required Amendments Public Health Council August 12, 2015 Jim Cremer, Deputy Director Erica Piedade, Director of Quality Assurance & Licensing, Overview
Resources for the Prevention and Treatment of Substance Use Disorders
Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug
1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve?
RI Mental Health Summit Lightning Round Q&A s June 8, 2015 Opiate Addiction Epidemic 1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve? 2) What would
Office-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
Opioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
Opioid Addiction & Corrections
Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and
Increasing Access to Opioid Addiction Treatment
Report to The Vermont Legislature Increasing Access to Opioid Addiction Treatment In Accordance with Act 75, 2013, Section 14b An Act Relating to Strengthening Vermont s Response to Opioid Addiction and
SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK
National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal
Bsafe Blackpool Community Safety and Drugs Partnership. Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13
Bsafe Blackpool Community Safety and Drugs Partnership Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13 Planning Framework Treatment plan Planning Framework Bsafe
Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program
Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program Substance- attributable mortality Presentation of the data Implications for our model of
State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff
State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff Funding Source: Grant No. 053773 Robert Wood Johnson Foundation Substance Abuse Policy Research
Joel Millard, DSW, LCSW Dave Felt, LCSW
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
MAT Counselor Education Course Exam Questions Packet Part 1
MAT Counselor Education Course Exam Questions Packet Part 1 Course No: Course Title: Course Objective: MA-1901P1 Medication-Assisted Treatment (MAT) Counselor Education Course Part 1 Includes primer on
An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009 Background Defining the problem: Opiates pain relievers (OxyContin,
Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:
Section XX. Definitions. Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended (1) by striking clause (ii) and inserting the following: (ii) The term qualifying practitioner
Use of Pharmacotherapies by Substance Abuse Treatment Facilities
Use of Pharmacotherapies by Substance Abuse Treatment Facilities Cathie E. Alderks, PhD Substance Abuse and Mental Health Services Administration Department of Health and Human Services November 2007 1
Reforming the Response To Substance Use: A Drug Policy for the 21 st Century
Reforming the Response To Substance Use: A Drug Policy for the 21 st Century 2015 NASADAD MEETING Charleston, SC June 2, 2015 David Mineta, Deputy Director Office of Demand Reduction Office of National
Washington State Interagency Opioid Working Plan
Washington State Interagency Opioid Working Plan INTRODUCTION January 2016 Washington State is currently experiencing an opioid abuse and overdose crisis involving prescription opioids and heroin. Approximately
The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community
The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community November 2014 INTRODUCTION The Heroin
The Changing Face of Opioid Addiction:
9th Annual Training and Educational Symposium September 6, 2012 The Changing Face of Opioid Addiction: A Review of the Research and Considerations for Care Mark Stanford, Ph.D. Santa Clara County Dept
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Various therapies are used in the
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all
Medication Assisted Treatment
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
A Drug Policy for the 21st Century. Office of National Drug Control Policy
A Drug Policy for the 21st Century October 18, 2014 International Nurses Society on Addictions Health Care Reform & Its Impact on Addictions Nursing: Navigating Change through the Rapids David K. Mineta,
Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to
2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
MEDICAL POLICY Treatment of Opioid Dependence
POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which
ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE
Medical Examiners Chapter 540-X-21 ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE CHAPTER 540-X-21 POLICY ON DATA 2000: GUIDELINES FOR THE TREATMENT OF OPIOID ADDICTION IN THE MEDICAL OFFICE 1
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB
Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts
Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in
Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD
Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,
Florida Alcohol and Drug Abuse Association. Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014
Florida Alcohol and Drug Abuse Association Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014 Florida Alcohol and Drug Abuse Association Founded in 1981 Currently has
Traci C. Green, PhD, MSc Jody Rich, MD, MPH
Traci C. Green, PhD, MSc Jody Rich, MD, MPH Strategic Plan highlights Comments & Responses from public, stakeholders Input and discussion Next steps Death rate for U.S. non-hispanic whites (USW), U.S.
Presentation to the Boston HIV Planning Council. Lydie Ultimo, MSW Director Bureau of Substance Abuse Services
Presentation to the Boston HIV Planning Council Lydie Ultimo, MSW Director Bureau of Substance Abuse Services Responsibilities of the Bureau of Substance Abuse Services License addiction treatment programs
Financial Disclosures
Opioid Agonist Therapy: To Maintain or Not To Maintain - A Case Discussion PCSS-MAT American Psychiatric Association Drs. Ed Salsitz, John Renner, Timothy Fong April 14, 2015 Financial Disclosures Edwin
Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services
Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services Maryland Integrative Learning Community Lynn H Albizo, Director of Public Affairs Maryland Addictions Directors
BUPRENORPHINE TREATMENT
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment
Opioids for Chronic Pain and Addiction Treatment Joseph Merrill M.D., M.P.H. University of Washington February 24, 2012 Outline for Today Opioids for pain treatment Trends Problems High dose prescribing
Update on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference